Accuray

Accuray Current Liabilities

The Current Liabilities of Accuray (ARAY) as of Oct 9, 2026 is 98.19 M USD. In the previous year, Current Liabilities was 138.06 M USD — a change of -28.88% (lower).

Current Liabilities

98.19 MUSD

YoY

-28.88%

Last updated:

Current Liabilities of Accuray is 2026 98.19 M USD. Current Liabilities of Accuray was 2025 138.06 M USD. It decreases by -28.88% lower compared to the previous year.

The Accuray Current Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Liabilities
Date
Current Liabilities
Jan 1, 2019
256.08 M USD
Jan 1, 2020
129.89 M USD
Jan 1, 2021
152.06 M USD
Jan 1, 2022
176.87 M USD
Jan 1, 2023
165.21 M USD
Jan 1, 2024
161.78 M USD
Jan 1, 2025
138.06 M USD
Jan 1, 2026
98.19 M USD
The Accuray Current Liabilities history
YEARCurrent LiabilitiesYoY
98.19 MUSD-28.88%
138.06 MUSD-14.66%
161.78 MUSD-2.07%
165.21 MUSD-6.59%
176.87 MUSD+16.32%
152.06 MUSD+17.07%
129.89 MUSD-49.28%
256.08 MUSD+0.97%
253.61 MUSD-43.24%
446.79 MUSD+53.53%
291.01 MUSD-1.05%
294.11 MUSD-9.59%
325.28 MUSD+211.68%
104.37 MUSD-28.42%
145.80 MUSD-41.12%
247.62 MUSD+231.36%
74.73 MUSD-2.57%
76.70 MUSD+8.12%
70.94 MUSD-9.59%
78.46 MUSD+73.51%
45.22 MUSD+131.06%
19.57 MUSD—
0.00USD—
0.00USD—
0.00USD—
Access this data via the Eulerpool API

Accuray Stock analysis

What does Accuray do? Accuray Inc is a company that was founded in 1990 and is headquartered in Sunnyvale, California. It is a global leader in providing precision solutions for the radiation treatment of cancer and other medical conditions. The company aims to develop revolutionary technologies that offer doctors and patients new treatment options for cancer and other diseases. History: Accuray was founded as a start-up company by a group of scientists who believed that cancer treatment was a crucial problem, with a lack of precision and control compromising the effectiveness of treatment. Therefore, they decided to develop a solution focused on precise, non-invasive radiation therapy. Since then, Accuray has continuously developed and introduced innovative technologies to enable better treatment for patients. Business model: Accuray's business model focuses on the development, sale, and service of radiation therapy products and solutions. The company provides global clinical support to ensure that customers receive the best possible application of Accuray technologies. Accuray primarily generates its revenues through the sale of radiation therapy systems and services. The company has over 800 employees worldwide and operates manufacturing locations in the US and China. Products and solutions: Accuray offers a wide range of products and solutions for clinical radiation therapy. These include the TomoTherapy systems, CyberKnife systems, and Radixact systems. The TomoTherapy systems have been specifically designed for precise and patient-specific radiation therapy applications. The technology enables precise dosage of radiation to tumor cells, protecting the surrounding healthy tissues. The CyberKnife system is used for the treatment of tumors that are difficult to access, such as those in the brain or spine. The robotic technology and precise radiation dosage enhance the effectiveness of treatment. With the Radixact system, Accuray offers a system that provides the latest generation of radiation therapy. The system delivers extremely precise dosages to the tumor while maximizing the preservation of surrounding tissues. Divisions: Accuray is divided into three business segments: Oncology Systems, Radiation Therapy Services, and Research Solutions. - Oncology Systems: Accuray offers the aforementioned TomoTherapy, CyberKnife, and Radixact systems, providing customers with the latest technology to treat various types of cancer. - Radiation Therapy Services: Accuray also provides a wide range of service and support offerings for its customers. These services include training, maintenance, technician support, and customer support. - Research Solutions: Accuray's research division provides academic institutions and research laboratories with access to a variety of technologies and solutions for radiation therapy and cancer research. Conclusion: Accuray has tirelessly worked to develop innovative technologies for radiation therapy, enabling better treatment and quality of life for patients. The company has made significant progress in recent years and now offers a wide range of products and solutions to its customers. Accuray has established itself as a global leader in radiation therapy and continues its success story with continuous research and innovation. Answer: Accuray Inc is a company that specializes in providing precision solutions for radiation treatment of cancer and other medical conditions. It was founded in 1990 and is headquartered in Sunnyvale, California. The company aims to develop innovative technologies that offer patients and doctors new treatment possibilities. Accuray has three divisions: Oncology Systems, Radiation Therapy Services, and Research Solutions. Their products include TomoTherapy, CyberKnife, and Radixact systems. Accuray is a leading global provider of radiation therapy solutions and continues to make advancements in research and innovation. Accuray is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Accuray stock

Current Liabilities of Accuray is 98.19 M USD in 2026.

Current Liabilities of Accuray changed from 138.06 M USD to 98.19 M USD, representing a -28.88% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Liabilities Accuray since 2006 – with annual values, charts, and detailed analysis.

Current liabilities are obligations due within one year, including accounts payable, short-term debt, and accrued expenses.

Current Liabilities's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Liabilities's Accuray historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — Accuray

All Key Metrics — Accuray